168 related articles for article (PubMed ID: 17960382)
1. The FLT3 inhibitor PKC412 in combination with cytostatic drugs in vitro in acute myeloid leukemia.
Möllgård L; Deneberg S; Nahi H; Bengtzen S; Jonsson-Videsäter K; Fioretos T; Andersson A; Paul C; Lehmann S
Cancer Chemother Pharmacol; 2008 Aug; 62(3):439-48. PubMed ID: 17960382
[TBL] [Abstract][Full Text] [Related]
2. Mechanisms of resistance against PKC412 in resistant FLT3-ITD positive human acute myeloid leukemia cells.
Stölzel F; Steudel C; Oelschlägel U; Mohr B; Koch S; Ehninger G; Thiede C
Ann Hematol; 2010 Jul; 89(7):653-62. PubMed ID: 20119833
[TBL] [Abstract][Full Text] [Related]
3. DNA repair contributes to the drug-resistant phenotype of primary acute myeloid leukaemia cells with FLT3 internal tandem duplications and is reversed by the FLT3 inhibitor PKC412.
Seedhouse CH; Hunter HM; Lloyd-Lewis B; Massip AM; Pallis M; Carter GI; Grundy M; Shang S; Russell NH
Leukemia; 2006 Dec; 20(12):2130-6. PubMed ID: 17066094
[TBL] [Abstract][Full Text] [Related]
4. Divergent cytotoxic effects of PKC412 in combination with conventional antileukemic agents in FLT3 mutation-positive versus -negative leukemia cell lines.
Furukawa Y; Vu HA; Akutsu M; Odgerel T; Izumi T; Tsunoda S; Matsuo Y; Kirito K; Sato Y; Mano H; Kano Y
Leukemia; 2007 May; 21(5):1005-14. PubMed ID: 17330105
[TBL] [Abstract][Full Text] [Related]
5. The FLT3 inhibitor PKC412 exerts differential cell cycle effects on leukemic cells depending on the presence of FLT3 mutations.
Odgerel T; Kikuchi J; Wada T; Shimizu R; Futaki K; Kano Y; Furukawa Y
Oncogene; 2008 May; 27(22):3102-10. PubMed ID: 18071308
[TBL] [Abstract][Full Text] [Related]
6. Combining the FLT3 inhibitor PKC412 and the triterpenoid CDDO-Me synergistically induces apoptosis in acute myeloid leukemia with the internal tandem duplication mutation.
Ahmad R; Liu S; Weisberg E; Nelson E; Galinsky I; Meyer C; Kufe D; Kharbanda S; Stone R
Mol Cancer Res; 2010 Jul; 8(7):986-93. PubMed ID: 20571062
[TBL] [Abstract][Full Text] [Related]
7. Breakdown of the FLT3-ITD/STAT5 axis and synergistic apoptosis induction by the histone deacetylase inhibitor panobinostat and FLT3-specific inhibitors.
Pietschmann K; Bolck HA; Buchwald M; Spielberg S; Polzer H; Spiekermann K; Bug G; Heinzel T; Böhmer FD; Krämer OH
Mol Cancer Ther; 2012 Nov; 11(11):2373-83. PubMed ID: 22942377
[TBL] [Abstract][Full Text] [Related]
8. Cotreatment with 17-allylamino-demethoxygeldanamycin and FLT-3 kinase inhibitor PKC412 is highly effective against human acute myelogenous leukemia cells with mutant FLT-3.
George P; Bali P; Cohen P; Tao J; Guo F; Sigua C; Vishvanath A; Fiskus W; Scuto A; Annavarapu S; Moscinski L; Bhalla K
Cancer Res; 2004 May; 64(10):3645-52. PubMed ID: 15150124
[TBL] [Abstract][Full Text] [Related]
9. CCL5 mediates target-kinase independent resistance to FLT3 inhibitors in FLT3-ITD-positive AML.
Waldeck S; Rassner M; Keye P; Follo M; Herchenbach D; Endres C; Charlet A; Andrieux G; Salzer U; Boerries M; Duyster J; von Bubnoff N
Mol Oncol; 2020 Apr; 14(4):779-794. PubMed ID: 31955503
[TBL] [Abstract][Full Text] [Related]
10. Receptor tyrosine kinase Axl is required for resistance of leukemic cells to FLT3-targeted therapy in acute myeloid leukemia.
Park IK; Mundy-Bosse B; Whitman SP; Zhang X; Warner SL; Bearss DJ; Blum W; Marcucci G; Caligiuri MA
Leukemia; 2015 Dec; 29(12):2382-9. PubMed ID: 26172401
[TBL] [Abstract][Full Text] [Related]
11. Preclinical and phase I results of decitabine in combination with midostaurin (PKC412) for newly diagnosed elderly or relapsed/refractory adult patients with acute myeloid leukemia.
Williams CB; Kambhampati S; Fiskus W; Wick J; Dutreix C; Ganguly S; Aljitawi O; Reyes R; Fleming A; Abhyankar S; Bhalla KN; McGuirk JP
Pharmacotherapy; 2013 Dec; 33(12):1341-52. PubMed ID: 23798029
[TBL] [Abstract][Full Text] [Related]
12. Bis(1H-indol-2-yl)methanones are effective inhibitors of FLT3-ITD tyrosine kinase and partially overcome resistance to PKC412A in vitro.
Heidel F; Lipka DB; Mirea FK; Mahboobi S; Grundler R; Kancha RK; Duyster J; Naumann M; Huber C; Böhmer FD; Fischer T
Br J Haematol; 2009 Mar; 144(6):865-74. PubMed ID: 19183186
[TBL] [Abstract][Full Text] [Related]
13. FMS-like tyrosine kinase 3-internal tandem duplication tyrosine kinase inhibitors display a nonoverlapping profile of resistance mutations in vitro.
von Bubnoff N; Engh RA; Aberg E; Sänger J; Peschel C; Duyster J
Cancer Res; 2009 Apr; 69(7):3032-41. PubMed ID: 19318574
[TBL] [Abstract][Full Text] [Related]
14. Synergy of FLT3 inhibitors and the small molecule inhibitor of LIM kinase1/2 CEL_Amide in FLT3-ITD mutated Acute Myeloblastic Leukemia (AML) cells.
Djamai H; Berrou J; Dupont M; Kaci A; Ehlert JE; Weber H; Baruchel A; Paublant F; Prudent R; Gardin C; Dombret H; Braun T
Leuk Res; 2021 Jan; 100():106490. PubMed ID: 33373830
[TBL] [Abstract][Full Text] [Related]
15. MDM2- and FLT3-inhibitors in the treatment of
Seipel K; Marques MAT; Sidler C; Mueller BU; Pabst T
Haematologica; 2018 Nov; 103(11):1862-1872. PubMed ID: 29976747
[TBL] [Abstract][Full Text] [Related]
16. Cabozantinib is selectively cytotoxic in acute myeloid leukemia cells with FLT3-internal tandem duplication (FLT3-ITD).
Lu JW; Wang AN; Liao HA; Chen CY; Hou HA; Hu CY; Tien HF; Ou DL; Lin LI
Cancer Lett; 2016 Jul; 376(2):218-25. PubMed ID: 27060207
[TBL] [Abstract][Full Text] [Related]
17. Midostaurin/PKC412 for the treatment of newly diagnosed FLT3 mutation-positive acute myeloid leukemia.
Luskin MR; DeAngelo DJ
Expert Rev Hematol; 2017 Dec; 10(12):1033-1045. PubMed ID: 29069942
[TBL] [Abstract][Full Text] [Related]
18. FLT3-ITD induces ara-C resistance in myeloid leukemic cells through the repression of the ENT1 expression.
Jin G; Matsushita H; Asai S; Tsukamoto H; Ono R; Nosaka T; Yahata T; Takahashi S; Miyachi H
Biochem Biophys Res Commun; 2009 Dec; 390(3):1001-6. PubMed ID: 19853583
[TBL] [Abstract][Full Text] [Related]
19. Association of the EGF-TM7 receptor CD97 expression with FLT3-ITD in acute myeloid leukemia.
Wobus M; Bornhäuser M; Jacobi A; Kräter M; Otto O; Ortlepp C; Guck J; Ehninger G; Thiede C; Oelschlägel U
Oncotarget; 2015 Nov; 6(36):38804-15. PubMed ID: 26462154
[TBL] [Abstract][Full Text] [Related]
20. Sensitivity toward sorafenib and sunitinib varies between different activating and drug-resistant FLT3-ITD mutations.
Kancha RK; Grundler R; Peschel C; Duyster J
Exp Hematol; 2007 Oct; 35(10):1522-6. PubMed ID: 17889720
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
